## Contents

1 Introduction ......................................................... 1
   Definitions ....................................................... 1
   Historical Aspects of Biomarkers ............................... 2
   Classification of Biomarkers .................................... 3
      Biological Marker as Response to Therapeutic Intervention 3
      Pharmacokinetic/Pharmacodynamics Biomarkers ............... 4
   Predictive Biomarkers .......................................... 4
   Valid Biomarkers ................................................ 5
   Types of Biomarkers ............................................. 5
      Genes as Biomarkers .......................................... 6
      Proteins as Biomarkers ...................................... 6
      Proteomics .................................................... 7
      DNA Biomarkers .............................................. 7
      Mitochondrial DNA ........................................... 7
      Mitochondrial Mutations .................................... 8
   RNA Biomarkers .................................................. 8
      Transcriptomics .............................................. 9
      MicroRNAs .................................................. 10
      Metabolomics ................................................. 10
      Glycomics .................................................... 11
      Single-Nucleotide Polymorphisms ............................ 12
      Haplotyping .................................................. 12
   Cell Biomarkers of Disease .................................... 13
   Stem Cell Biomarkers .......................................... 13
   Cancer Stem Cell Biomarkers .................................. 14
   Endoglin as a Functional Biomarker of Stem Cells ........... 14
   p75NTR as a Biomarker to Isolate Adipose Tissue-Derived Stem Cells ................................................. 15
   Protein Expression Profile as Biomarker of Stem Cells ....... 15
   STEMPRO® EZChek™ for Analysis of Biomarkers of hESCs .... 15
   SSEA-4 as Biomarker of MSCs .................................. 16
   Autoantibodies as Biomarkers of Autoimmune Diseases ....... 16
The Ideal Biomarker ........................................ 17
Biomarkers and Systems Biology .......................... 18
    Systems Biology Approach to Biomarker Identification .......... 19
Relation of Biomarkers to Other Technologies and Health care .... 20
    Biomarkers and Translational Medicine .......................... 20
    Limitations of Use of Biomarkers in Health Care ................. 20

2 Technologies for Discovery of Biomarkers ............. 23
Introduction ................................................ 23
Detection of Biomarkers in Tissues and Body Fluids ............ 23
Disease Biomarkers in Breath ................................ 23
    Portable Breath Test for Volatile Organic Compounds ............ 24
    Detection of Breath Biomarkers by Sensation Technology .......... 24
    Detection of Breath Biomarkers Optical Frequency Comb Spectroscopy ......................................................... 25
Genomic Technologies ........................................ 25
    Gene Expression ........................................... 25
    Tissue Microarrays for Study of Biomarkers ...................... 28
Epigenomic Technologies ..................................... 28
    Discovery of Methylation Biomarkers ............................ 29
Proteomic Technologies ....................................... 30
    2D GE .................................................... 31
    Isotope-Coded Affinity Tags .................................. 32
    Mass Spectrometry .......................................... 33
    Liquid Chromatography–MS Combination .......................... 37
    Protein Tomography ......................................... 37
    Protein Biochips/Microarrays and Biomarkers .................... 38
    Real-Time PCR for Quantification of Protein Biomarkers ......... 39
    Magnetic Beads for Protein Biomarker Discovery ................. 40
    CellCarta® Proteomics Platform ................................ 40
    MASStermind™ .............................................. 41
Search for Biomarkers in Body Fluids .......................... 41
Challenges and Strategies for Discovery of Protein Biomarkers in Plasma ................................................................. 41
Biomarkers in the Urinary Proteome ............................. 47
Peptides in Body Fluids and Tissues as Biomarkers of Disease ... 47
Verification for Interlaboratory Reproducibility of Protein Biomarkers ................................................................. 49
Significance of Similar Protein Biomarkers in Different Tissues ... 50
Glycomic Technologies ........................................ 51
Metabolomic Technologies ..................................... 51
    Mass Spectrometry-Based Kits for Discovery of Metabolic Biomarkers in Plasma ................................................. 52
Urinary Profiling by Capillary Electrophoresis .................... 52
Lipid Profiling ................................................ 53
Role of Metabolomics in Biomarker Identification and Pattern Recognition .................. 53
Validation of Biomarkers in Large-Scale Human Metabolomics Studies .................. 54
Lipidomics ........................................... 54
Fluorescent Indicators for Biomarkers ........................................... 55
Molecular Imaging Technologies ........................................... 56
- Computer Tomography ........................................... 56
- Magnetic Resonance Imaging ........................................... 57
- Positron Emission Tomography ........................................... 57
Advantages of Imaging Biomarkers ........................................... 58
- Monitoring In Vivo Gene Expression by Molecular Imaging ........................................... 58
- Molecular Imaging In Vivo as a Biomarker ........................................... 59
Challenges and Future Prospects of Molecular Imaging ........................................... 59
Molecular Imaging in Clinical Practice ........................................... 60
Nuclear Magnetic Resonance ........................................... 61
- Chemical Derivatization to Enhance Biomarker Detection by NMR ........................................... 61
- Fluxomics by Using NMR ........................................... 62
Nanobiotechnology ........................................... 62
- Nanomaterials for Biolabeling ........................................... 63
- Nanoproteomics and Biomarkers ........................................... 65
- Nanoparticles for Molecular Imaging ........................................... 66
- Nanoparticles for Discovering Biomarkers ........................................... 67
Nucleoprotein Nanodevices for Detection of Cancer Biomarkers ........................................... 67
Future Prospects of Application of Nanobiotechnology for Biomarkers ........................................... 67
Bioinformatics ........................................... 68
- Biomarker Workflow Guide ........................................... 68
- Analysis of Microarray Data for Selecting Useful Biomarkers ........................................... 68
Role of Bioinformatics in Discovery of Proteomic Biomarkers ........................................... 69
Role of Bioinformatics in Detection of Cancer Biomarkers ........................................... 70
Biomarker Databases ........................................... 70
Gene Networks as Biomarkers ........................................... 71
Pitfalls in the Discovery and Development of Biomarkers ........................................... 71

3 Biomarkers and Molecular Diagnostics ........................................... 73
Introduction ........................................... 73
Molecular Diagnostic Technologies ........................................... 73
- Polymerase Chain Reaction ........................................... 73
- Combined PCR–ELISA ........................................... 75
- Non-PCR Methods ........................................... 76
- Transcription-Mediated Amplification ........................................... 77
Rapid Analysis of Gene Expression ........................................... 77
WAVE Nucleic Acid Fragment Analysis System ........................................... 77
DNA Probes with Conjugated Minor Groove Binder ........ 78
Rolling-Circle Amplification Technology .................... 79
Circle-to-Circle Amplification .................................. 81
Biochips and Microarrays ........................................ 81
Detection and Expression Profiling of miRNA .................. 83
Real-Time PCR for Expression Profiling of miRNAs ............ 83
Use of LNA to Explore miRNA ...................................... 84
Microarrays for Analysis of miRNA Gene Expression .......... 84

4 Biomarkers for Drug Discovery and Development ............... 87
Introduction ......................................................... 87
Biomarker Technologies for Drug Discovery .................... 88
  Proteomics-Based Biomarkers for Drug Discovery .......... 88
  Chemoproteomics ................................................. 89
  Transcriptomics for Drug Discovery ......................... 89
  Metabolomics for Drug Discovery .............................. 90
Biomarkers and Drug Safety ...................................... 91
  Biomarkers of Adverse Drug Reactions ....................... 91
Applications of Biomarkers in Drug Safety Studies .......... 91
Genomic Technologies for Toxicology Biomarkers ............. 92
Proteomic Technologies for Toxicology Biomarkers .......... 93
Metabolomic Technologies for Toxicology Biomarkers ....... 93
Integration of Genomic and Metabonomic Data to Develop
  Toxicity Biomarkers ............................................ 94
  Toxicology Studies Based on Biomarkers ...................... 94
Applications of Biomarkers for Drug Development ............ 99
  Application of Metabonomics/Metabolomics for Drug
  Development ....................................................... 99
Role of Pharmacokinetic/Pharmacodynamic Biomarkers in
  Drug Development ................................................. 100
Molecular Imaging as a Biomarker in Drug Development .... 101
Biomarkers in Clinical Trials .................................... 105
Application of Biomarkers by the Pharmaceutical Companies .. 108
Drug Development in Cardiovascular Disorders ............... 109
Drug Development in Neurological Disorders .................. 109
Future Prospects of Biomarker-Based Drug Development ..... 110

5 Role of Biomarkers in Health Care ............................. 115
Introduction ......................................................... 115
Biomarkers of Inflammation ..................................... 116
Biomarkers of Oxidative Stress .................................. 116
  Oxidative DNA Damage ........................................ 116
  Proteins as Biomarkers of Oxidative Stress in Diseases .... 117
  1,4-Dihydroxynonane Mercapturic Acid ..................... 117
Biomarkers in Metabolic Disorders ................................ 117
Biomarkers of Acute Intermittent Porphyria ........................................ 117
Liver X Receptors ........................................................................... 118
Biomarkers of Diabetes Mellitus ...................................................... 118
Biomarkers of Metabolic Syndrome .................................................. 122
Biomarkers in Immune Disorders .................................................... 123
  Biomarkers of Failure of Transplanted Organs ............................... 123
  Systemic Lupus Erythematosus ..................................................... 126
Biomarkers of Musculoskeletal Disorders ......................................... 129
  Biomarkers of Rheumatoid Arthritis ............................................. 129
  Biomarkers of Spondylarthitis ..................................................... 130
  Biomarkers of Osteoarthritis ....................................................... 131
Biomarkers of Osteoporosis ............................................................ 132
  Dual X-Ray Absorptiometry ........................................................ 133
  Bone Imaging with Quantitative CT and MRI ............................... 133
  Assays for Detection of Biomarkers of Osteoporosis ..................... 134
Biomarkers of Infectious Diseases ................................................. 134
  Application of Proteomics for Discovering Biomarkers of Infections .......................... 137
  Systemic Inflammatory Response Syndrome ................................ 138
  Tuberculosis ............................................................................... 138
  Biomarkers of Viral Infections .................................................... 141
  Biomarkers in Parasitic Infections .............................................. 145
Biomarkers of Liver Disease ............................................................ 147
  Breath Biomarkers of Liver Disease ............................................. 147
  Biomarkers of Viral Hepatitis B and C ........................................... 148
  Biomarkers of Liver Injury .......................................................... 149
  Biomarkers of Liver Cirrhosis ..................................................... 149
  FibroMax ................................................................................... 149
Biomarkers of Pancreatitis .............................................................. 150
Biomarkers of Renal Disease ........................................................... 150
  Cystatin C as Biomarker of Glomerular Filtration Rate ............... 151
  Proteomic Biomarkers of Acute Kidney Injury ......................... 151
  Biomarkers of Lupus Nephritis .................................................. 152
  Biomarkers of Diabetic Nephropathy ......................................... 152
Biomarkers of Pulmonary Diseases ................................................. 152
  Biomarkers of Oxidative Stress in Lung Diseases ....................... 154
  Biomarkers of Survival in Acute Respiratory Distress Syndrome ... 154
  Pulmonary Surfactant Proteins as Biomarkers for Lung Diseases ... 155
  Biomarkers of Chronic Obstructive Pulmonary Disease ............... 156
  Biomarkers of Asthma ............................................................... 158
  Biomarkers for Cystic Fibrosis ................................................... 161
  Biomarkers of Pulmonary Embolism .......................................... 162
Biomarkers in Obstetrics and Gynecology ....................................... 163
  Biomarkers for Preeclampsia ..................................................... 163
  Biomarkers of Premature Birth .................................................. 166
<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immunologic Biomarkers of Cancer</td>
<td>196</td>
</tr>
<tr>
<td>Molecular Diagnostic Techniques for Cancer</td>
<td>196</td>
</tr>
<tr>
<td>Technologies for Detection of Cancer Biomarkers</td>
<td>197</td>
</tr>
<tr>
<td>Genomic Technologies for Cancer Biomarkers</td>
<td>197</td>
</tr>
<tr>
<td>Tissue Microarrays for Study of Cancer Biomarkers</td>
<td>202</td>
</tr>
<tr>
<td>Molecular Fingerprinting of Cancer</td>
<td>203</td>
</tr>
<tr>
<td>Biomarkers of Inflammation in Cancer</td>
<td>204</td>
</tr>
<tr>
<td>Proteomic Technologies for Detecting Biomarkers of Cancer</td>
<td>205</td>
</tr>
<tr>
<td>Metabolomic Biomarkers of Cancer</td>
<td>215</td>
</tr>
<tr>
<td>Epitomics for the Early Detection of Cancer</td>
<td>217</td>
</tr>
<tr>
<td>Detection of Biomarkers of DNA Methylation</td>
<td>217</td>
</tr>
<tr>
<td>Nanobiotechnology for Early Detection of Cancer to Improve Treatment</td>
<td>222</td>
</tr>
<tr>
<td>Selective Expression of Biomarkers by Cancer Compared with Normal Tissues</td>
<td>223</td>
</tr>
<tr>
<td>Ultrasound Radiation to Enhance Release of a Tumor Biomarker</td>
<td>223</td>
</tr>
<tr>
<td>In Vivo Imaging of Cancer Biomarkers</td>
<td>224</td>
</tr>
<tr>
<td>Kallikrein Gene Family and Cancer Biomarkers</td>
<td>226</td>
</tr>
<tr>
<td>Circulating Cancer Cells in Blood as Biomarkers of Cancer</td>
<td>226</td>
</tr>
<tr>
<td>Applications of Cancer Biomarkers</td>
<td>227</td>
</tr>
<tr>
<td>Use of Biomarkers for Cancer Classification</td>
<td>228</td>
</tr>
<tr>
<td>Use of Biomarkers for Early Detection of Cancer</td>
<td>228</td>
</tr>
<tr>
<td>Application of Biomarkers for Cancer Diagnosis</td>
<td>229</td>
</tr>
<tr>
<td>Applications of Biomarkers for Cancer Diagnosis Plus Therapy</td>
<td>231</td>
</tr>
<tr>
<td>Biomarkers for Assessment of Efficacy of Cancer Therapy</td>
<td>232</td>
</tr>
<tr>
<td>Biomarkers of Angiogenesis for Developing Antiangiogenic Therapy</td>
<td>234</td>
</tr>
<tr>
<td>Biomarkers of Drug Resistance in Cancer</td>
<td>237</td>
</tr>
<tr>
<td>Biomarkers of Radiation Exposure</td>
<td>238</td>
</tr>
<tr>
<td>Role of Biomarkers in Drug Development in Oncology</td>
<td>239</td>
</tr>
<tr>
<td>Molecular Imaging of Tumor as a Guide to Drug Development</td>
<td>239</td>
</tr>
<tr>
<td>Biomarkers in Plucked Hair for Assessing Cancer Therapy</td>
<td>241</td>
</tr>
<tr>
<td>Molecular Targets of Anticancer Drugs as Biomarkers</td>
<td>241</td>
</tr>
<tr>
<td>Safety Biomarkers in Oncology Studies</td>
<td>242</td>
</tr>
<tr>
<td>Role of Biomarkers in Phase I Clinical Trials of Anticancer Drugs</td>
<td>242</td>
</tr>
<tr>
<td>Biomarkers According to Location/Type of Cancer</td>
<td>243</td>
</tr>
<tr>
<td>Bladder Cancer Biomarkers</td>
<td>243</td>
</tr>
<tr>
<td>Brain Cancer Biomarkers</td>
<td>244</td>
</tr>
<tr>
<td>Breast Cancer Biomarkers</td>
<td>250</td>
</tr>
<tr>
<td>Cervical Cancer Biomarkers</td>
<td>268</td>
</tr>
<tr>
<td>Gastrointestinal Cancer Biomarkers</td>
<td>269</td>
</tr>
<tr>
<td>Head and Neck Cancer</td>
<td>275</td>
</tr>
<tr>
<td>Leukemia Biomarkers</td>
<td>276</td>
</tr>
<tr>
<td>Liver Cancer Biomarkers</td>
<td>281</td>
</tr>
<tr>
<td>Lung Cancer Biomarkers</td>
<td>282</td>
</tr>
</tbody>
</table>
Malignant Pleural Mesothelioma ........................................ 291
Melanoma Biomarkers .................................................... 292
Nasopharyngeal Carcinoma Biomarkers ............................... 294
Oral Cancer Biomarkers .................................................. 296
Ovarian Cancer Biomarkers ............................................. 297
Pancreatic Cancer Biomarkers ......................................... 302
Prostate Cancer .......................................................... 306
Renal Cancer Biomarkers ............................................... 317
Thyroid Cancer Biomarkers ............................................ 320
Role of the NCI in Biomarkers of Cancer ............................. 322
Cancer Genetic Markers of Susceptibility Project .................. 322
Oncology Biomarker Qualification Initiative ....................... 322
Role of NCI in Cancer Biomarker Development and Validation .. 323
Future Prospects for Cancer Biomarkers ............................ 324
Cancer Biomarker Research at Academic Institutions ............ 324
Future Prospects and Challenges in the Discovery of Cancer Biomarkers ........................................ 325

7 Biomarkers of Disorders of the Nervous System .................. 327
Introduction ..................................................................... 327
Discovery of Biomarkers of Neurological Disorders ............... 327
Biomarker Identification in the CSF Using Proteomics .......... 328
Biomarker Identification in the CSF Using Lipidomics .......... 329
Cerebral Microdialysis for the Study of Biomarkers of
Cerebral Metabolism ....................................................... 329
Detection of Protein Biomarkers of CNS Disorders in the Blood . 330
Brain Imaging for Detection of Biomarkers ........................... 330
Data Mining for Biomarkers of Neurological Disorders .......... 331
Antibodies as Biomarkers in Disorders of the Nervous System .. 331
Biomarkers of Neural Regeneration .................................... 331
Biomarkers of Disruption of Blood–Brain Barrier .................. 332
Biomarkers of Neurotoxicity ............................................. 333
Glial Fibrillary Acidic Protein as Biomarker of Neurotoxicity . 333
Single-Stranded DNA as a Biomarker of Neuronal Apoptosis . 334
Biomarkers of Neurodegenerative Disorders ........................ 334
Biomarkers of Alzheimer Disease ...................................... 335
Biomarkers of Parkinson Disease ...................................... 354
Biomarkers of Huntington Disease .................................... 358
Biomarkers of Wilson Disease ......................................... 360
Biomarkers of Amyotrophic Lateral Sclerosis ....................... 360
Biomarkers of Dementia in HIV-1-Infected Patients ............... 364
Biomarkers of Prion Diseases ........................................... 364
Biomarkers of Multiple Sclerosis ...................................... 365
Antibodies in Multiple Sclerosis ....................................... 366
T Cells as Biomarkers of Multiple Sclerosis ....................... 368
Matrix Metalloproteinases as Biomarkers in Multiple Sclerosis .................................................. 369
Gelsolin as a Biomarker of Multiple Sclerosis ............................................................. 369
Gene Expression Profiling of Biomarkers in Multiple Sclerosis .................................................. 369
Serum Proteomic Pattern Analysis in Multiple Sclerosis ......................................................... 370
Biomarkers of Remyelination and Repair ................................................................................. 370
Biomarkers of Response to Therapy of Multiple Sclerosis ......................................................... 371
Concluding Remarks and Future Perspective of Biomarkers of Multiple Sclerosis ................ 371

Biomarkers of Stroke ............................................................................................................... 372
Biomarkers of Intracerebral Hemorrhage ................................................................................. 374
Biomarkers of Hypoxic Brain Damage ..................................................................................... 374
Brain Natriuretic Peptide as a Biomarker of Cardioembolic Stroke ........................................ 375
Brain Lactate and N-Acetylaspartate as Biomarkers of Stroke ................................................ 375
Intercellular Adhesion Molecule 1 as Biomarker of Ischemic Stroke ...................................... 375
Lp-PLA2 and CRP as Biomarkers of Stroke ............................................................................. 376
Neuroserpin Polymorphisms as a Biomarker of Stroke .......................................................... 376
NMDA Receptors as Biomarkers of Excitotoxicity in Stroke .................................................. 376
Nucleosomes as Biomarkers of Stroke .................................................................................... 377
PARK7 and Nucleoside Diphosphate Kinase A as Biomarkers of Stroke .............................. 377
Visinen-Like Protein 1 ............................................................................................................ 378
Gene Expression in Blood Following Ischemic Stroke ............................................................ 378
Future Prospects of Biomarkers of Stroke .............................................................................. 379

Biomarkers of Traumatic Brain Injury ................................................................................... 380
Technologies for Identification of Biomarkers of TBI .......................................................... 381
Biomarkers of TBI .................................................................................................................... 383
Biomarkers of Inflicted TBI in Infants ...................................................................................... 384
Clinical Applications of Biomarkers of TBI .......................................................................... 385

Biomarkers of CNS Infections ................................................................................................. 385
Biomarkers of CNS HIV Infection .......................................................................................... 386
Biomarkers of Bacterial Meningitis ......................................................................................... 386

Biomarkers of Epilepsy ............................................................................................................ 387
Genetic Epilepsies ................................................................................................................... 387
Biochemical Markers of Epilepsy ............................................................................................ 387
Imaging Biomarkers of Epilepsy ............................................................................................... 388

Biomarkers of Normal Pressure Hydrocephalus ..................................................................... 388
Biomarkers of Retinal Disorders .............................................................................................. 389
Biomarkers of Age-Related Macular Degeneration ................................................................ 389

Biomarkers of Autism .............................................................................................................. 390
Biomarkers of Sleep Disorders ................................................................................................. 391
Biomarker of Excessive Daytime Sleepiness .......................................................................... 391
Biomarkers of Obstructive Sleep Apnea .................................................................................... 392

Biomarkers of Restless Legs Syndrome .................................................................................. 392

Biomarkers of Psychiatric Disorders ....................................................................................... 393
Contents

8 Biomarkers of Cardiovascular Disorders .................................. 397
   Introduction ........................................................................... 397
   Epidemiology of Cardiovascular Disease .............................. 397
   Biomarkers of Cardiovascular Diseases ................................. 398
   Genetic Biomarkers of Cardiovascular Disorders .................. 399
   Methods for Identification of Cardiovascular Biomarkers ....... 401
      Application of Proteomics for Biomarkers of Cardiovascular
      Disease ............................................................................... 401
      Detection of Biomarkers of Myocardial Infarction in Saliva
      by a Nanobiochip ............................................................... 402
      Metabolomic Technologies for Biomarkers of Myocardial
      Ischemia .............................................................................. 402
      Imaging Biomarkers of Cardiovascular Disease ................... 403
   Applications of Biomarkers of Cardiovascular Disease ........... 404
      Biomarkers for Ischemic Heart Disease and Myocardial Infarction
      ................................................................. 404
      Biomarkers of Congestive Heart Failure .............................. 409
      Biomarkers for Atherosclerosis .......................................... 413
      Biomarkers of Risk Factors for Coronary Heart Disease ....... 416
      Biomarkers for Pulmonary Arterial Hypertension ............... 419
      Genetic Biomarkers for Cardiovascular Disease .................. 420
      Multiple Biomarkers for Prediction of Death
      from Cardiovascular Disease .............................................. 425
   Role of Biomarkers in the Management of Cardiovascular Disease .. 426
   Role of Biomarkers in the Diagnosis of Myocardial Infarction ..... 426
   Role of Biomarkers in the Prevention of Cardiovascular Disease .. 426
   Molecular Signature Analysis in Management
   of Cardiovascular Diseases .................................................. 427
   C-Reactive Protein as Biomarker of Response to Statin Therapy .. 427
   Role of Circulating Biomarkers and Mediators
   of Cardiovascular Dysfunction ............................................. 428
   Use of Biomarkers in the Management of Peripheral Arterial
   Disease .............................................................................. 429
   Use of Biomarkers in the Management of Hypertension .......... 429
   Use of Protein Biomarkers for Monitoring Acute
   Coronary Syndromes .......................................................... 429
   Use of Multiple Biomarkers for Monitoring of Cardiovascular
   Disease .............................................................................. 430
   Future Prospects for Cardiovascular Biomarkers .................... 431
   Cardiovascular Biomarker Consortium .................................. 431
   Systems Approach to Biomarker Research in Cardiovascular
   Disease .............................................................................. 432
9 Biomarkers and Personalized Medicine ........................................... 433
   Introduction .............................................................................. 433
   Pharmacogenetics ..................................................................... 434
      Biomarkers and Pharmacogenetics .......................................... 434
   Pharmacogenomics .................................................................. 436
   Pharmacoproteomics .................................................................. 436
      Single-Cell Proteomics for Personalized Medicine .................. 437
   Role of Biomarkers in Development of Personalized Drugs .......... 438
      Use of Biomarkers for Developing MAb Therapy in Oncology .... 438
   Biobanking, Biomarkers, and Personalized Medicine in EU .......... 438
   Expression Signatures as Diagnostic/Prognostic Tools ................. 440
   Biomarkers for Monitoring Response to Therapy ......................... 440
   Drug Rescue by Biomarker-Based Personalized Medicine ............. 441
   Future Role of Biomarkers in Personalized Medicine .................. 442

10 Regulatory Issues ...................................................................... 443
   Introduction .............................................................................. 443
   Biomarker Validation .................................................................. 443
      FDA Criteria for a Valid Biomarker .......................................... 444
      Role of NIST in Validation of Cancer Biomarkers ................. 445
      Quality Specifications for BNP and NT-proBNP as Cardiac
      Biomarker Assays .................................................................... 446
   FDA Perspective of Biomarkers in Clinical Trials ......................... 447
   FDA and Predictive Medicine ...................................................... 449
   Biomarkers and FDA’s Voluntary Genomic Data Submission .......... 449
   Role of Imaging Biomarkers in Approval of Drugs ......................... 450
   FDA Critical Path Initiative and Biomarker R&D ......................... 451
      FDA Consortium Linking Genetic Biomarkers to Serious
      Adverse Events ........................................................................ 451
      Oncology Biomarker Qualification Initiative ......................... 452
      Critical Path Initiative ............................................................. 453
      From Validated Biomarker Assay to a Clinical Laboratory
      Diagnostic ............................................................................... 456
      Fast Path Programs .................................................................. 456
      Need for a Single Federal Agency to Oversee Biomarker Field .... 457

References .................................................................................. 459

Subject Index ............................................................................. 487
The Handbook of Biomarkers
Jain, K.K.
2010, XX, 492 p., Hardcover
A product of Humana Press